Cost-effectiveness of edaravone dexborneol sublingual tablet versus concentrated solution for injection for the treatment of acute ischemic stroke in China
BackgroundEdaravone dexborneol sublingual tablet (EDSL) is a novel therapy for acute ischemic stroke (AIS), proven effective and safe. Its convenient dosage form also provides an alternative administration option, helping to enhance treatment accessibility. This study evaluates the cost-effectivenes...
Tallennettuna:
| Päätekijät: | , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Frontiers Media S.A.
2025-11-01
|
| Sarja: | Frontiers in Pharmacology |
| Aiheet: | |
| Linkit: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1661581/full |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|